tiprankstipranks
Trending News
More News >
NervGen Pharma (NGENF)
OTHER OTC:NGENF
US Market

NervGen Pharma (NGENF) Income Statement

Compare
58 Followers

NervGen Pharma Income Statement

Last quarter (Q4 2024), NervGen Pharma's total revenue was C$0.00, a decrease of ― from the same quarter last year. In Q4, NervGen Pharma's net income was C$-8.61M. See NervGen Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
C$ 0.00C$ 0.00C$ 0.00C$ 0.00C$ 0.00
Gross Profit
C$ -83.80KC$ -145.00KC$ -115.11KC$ -42.63KC$ -39.65K
Operating Expenses
C$ 24.85MC$ 17.63MC$ 23.03MC$ 12.81MC$ 11.20M
Depreciation and Amortization
C$ 83.80KC$ 145.00KC$ 115.11KC$ 42.63KC$ 39.65K
EBITDA
C$ -23.92MC$ -17.72MC$ -20.09MC$ -12.77MC$ -11.16M
Operating Income
C$ -24.93MC$ -17.78MC$ -22.82MC$ -12.87MC$ -11.19M
Other Income/Expenses
C$ 926.10KC$ -4.61MC$ 2.30MC$ 84.65KC$ 9.74K
Pretax Income
C$ -24.01MC$ -22.38MC$ -20.72MC$ -12.73MC$ -11.19M
Net Income
C$ -24.01MC$ -22.38MC$ -18.11MC$ -12.64MC$ -11.18M
Per Share Metrics
Basic EPS
C$ -0.36C$ -0.38C$ -0.34C$ -0.32C$ -0.35
Diluted EPS
C$ -0.36C$ -0.38C$ -0.34C$ -0.32C$ -0.35
Weighted Average Shares Outstanding
67.32M 59.29M 52.65M 39.29M 32.11M
Weighted Average Shares Outstanding (Diluted)
67.32M 59.29M 52.65M 39.29M 32.11M
Currency in CAD

NervGen Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis